

# Epidemiological and Clinicopathological Features of Breast Cancer in Mauritania

**Selma MOHAMED BRAHIM**

Université de Nouakchott Al-Asriya, Faculté des Sciences et Techniques

**Cheikh Tijani HAMED**

Université de Nouakchott Al-Asriya, Faculté des Sciences et Techniques

**EkhtElbenina ZEIN**

Centre National d'Oncology (CNO).

**Malak SALAME**

Université de Nouakchott Al-Asriya, Faculté des Sciences et Techniques

**Fatimetou VETEN**

Université de Nouakchott Al-Asriya, Faculté des Sciences et Techniques

**Mohamed Vall ZEIN**

Centre National d'Oncology (CNO).

**Meriem KHYATTI**

Institut Pasteur du Maroc.

**Ahmed HOUMEIDA** (✉ [houmeida@hotmail.com](mailto:houmeida@hotmail.com))

Université de Nouakchott Al-Asriya, Faculté des Sciences et Techniques

**Ahmedou TOLBA**

Centre National d'Oncology (CNO).

---

## Research Article

**Keywords:** Breast cancer (BC), TNBC, women, Mauritania

**Posted Date:** March 1st, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-257498/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Background

Breast cancer is the leading cause of death in African women. The aim of this retrospective study was to assess the incidence, clinico-pathological characteristics, risk factors and outcome of breast cancer in Mauritania.

## Methods

Demographic and clinico-pathological features of breast cancer were gathered from 11174 patient files of all cancer types referred to the Centre National d'Oncologie (CNO) between January 2009 and December 2020.

## Results

Breast cancer was the most common type of cancer identified in women (30.7%). The disease incidence increased from 69 in 2009 to 209 in 2020 with a mean age of 49 year at cancer detection. Grade 3 tumor was diagnosed in 31.8% patients. Stage 3 and metastatic stage were found respectively in 44.9 % and 22.6% of screened women. 40.4% of cancer patients with satisfactory immunohistochemical data were triple negative breast cancer (TNBC) but no significant variation was found in these features between TNBC and non TNBC groups. A 3-year survival rate of 63% was observed.

## Conclusions

These results support the already published studies on the likely genetic basis of breast cancer in our population.

## Background

Although breast cancer (BC) survival is continually improving in developed states[1], the disease remained a leading cause of death in women from low- and middle-income countries likely due to a late diagnosis, often at advanced stage, combined to the scarcity of adequate and personalized primary treatment[2-3]. The incidence and mortality rate from BC was also affected by other major risk factors such as age, family history and ethnic ascendance[4-6]. However, studies on the underlying etiologies and the prospect of recovery from the disease remained particularly limited in sub-Saharan African women[7-9].

We present here data gathered from the registries of the Centre National d'Oncologie (CNO), on the frequency, demographics, clinico-pathological features and prognosis of breast cancer in Mauritania. These variables were specifically evaluated in triple negative breast cancer (TNBC) patients and compared with data from non TNBC women.

## Methods

Medical files of 11174 patients of all cancer types followed at the CNO, the only referring center for oncology in the country, were examined from the period of January 2009, date of opening of the center, through to December 2020. Cancer type, Name and date of birth of each patient were recorded.

In this study, detailed demographic and clinical characteristics, available at the center only from 01/2017 onwards, were analyzed for breast cancer patients and included age at diagnosis, body mass index (BMI) calculated as weight in kilograms/height in meters square (kg/m<sup>2</sup>), family history of the disease, cancer staging, histological grading, received therapy and clinical outcome. Immunohistochemical staining (IHC) was carried out on patient tissue samples embedded in paraffin blocks. Patients with no slides or ambiguous pattern were excluded. Grading (from T0 to T4) was performed according to the American joint committee on cancer /Union for international cancer control (AJCC/UICC) systems. Evaluation (from 0 to 4) of cancer stage used TNM staging. Triple negative breast cancer (TNBC) subjects were patients with slides showing no antibody staining or a tumor cells fluorescence of less than 1% for, concurrently, receptors of estrogen (ER), progesterone (PR) and hormone epidermal growth factor receptor 2 (HER-2).

Local or distant recurrence was defined by the time span from the end of primary treatment to date of return of the disease in the original site or other part of the body respectively.

Survival duration was determined as the period between the dates of BC diagnosis to the patient death if recorded or the last missed appointment and loss of follow up.

Data analysis was performed by SPSS version 23.0 software (Chicago, Ill). Comparison among clinical variables between TNBC and no TNBC was performed with Person Chi-square test using a statistical significance of  $p < 0.05$ .

## Results

### Demographic findings

Globally, out of the 11174 cancer files of all types (5989 women and 5185 men) referred to CNO during the period from January 2009 to December 2020, breast cancer was found in 1853 (16.58 %) patients (Fig. 1). With a proportion of 30.75%, BC was the most common type of cancer identified in the female group. In the male group, the disease was much less frequent with only 11 cases (0.21%) of the total cancer male carriers. Overall, 99.79 % of breast cancer cases were in females and less than 1% in males.

The incidence rate showed a steady increase of the annual number of new women breast cancer cases with 69, 160 and 209 BC diagnosed in 2009, 2015 and 2020 respectively (Fig. 2).

Adequate demographic and clinico-pathological characteristic, available from 01/2017 to 12/2020, concerned 793 women (Table 1). Median age of patients, at cancer detection, was 49 years with most breast cancers diagnosed between 35 to 55 years (52.4%) followed by the group of above 55 years (31%). The fraction in the 20s to 35s age represented 16.6%. Premenopausal status was observed

in 63.7% of the records. Family history (first- and second-degree relatives with breast cancer) was reported by 95 (14.5%) of patients and 388 women (59%) had parents with shared common ascendant. Of 785 patients, 31.3 % were overweight and 49.3 % obese.

Table 1  
Demographic and clinico-pathological characteristic of the study population

<i>Parameters</i>	<i>Cases (N)</i>	<i>Percentage(%)</i>
<b>Age, years(N = 793)</b>		
< 35	132	16,6
[35– 55]	416	52,4
> 55	245	31
<b>Menopausal status(N = 793)</b>		
Premenopausal	505	63,7
Postmenopausal	288	36,3
<b>Family history (N = 658)</b>		
Present	95	14,5
Absent	563	85,5
<b>Consanguinity (N = 658)</b>		
Yes	388	59
Non	270	41
<b>Body Mass Index kg/m<sup>2</sup>(N = 785)</b>		
Underweight < 18	24	3
Normal weight [18– 25[	128	16,3
Overweight [25– 30[	246	31,4
Obesity [30– 35]	354	45,1
Morbidobesity > 35	33	4,2
<b>Ethnicity (N = 793)</b>		
White Moors	397	50,1
Black Moors	263	33,2
Black Africans	133	16,7
<b>Breast affected (N = 793)</b>		
Right	417	52,6
Left	351	44,3

<i>Parameters</i>	<i>Cases (N)</i>	<i>Percentage(%)</i>
bilateral	25	3,1
<b>Tumor size (N = 404)</b>		
< 5 cm	275	68,1
> 5cm	129	31,9
<b>Histologicalgrading (N = 586)</b>		
Grade I	67	11,4
Grade II	334	57
Grade III	185	31,6
<b>Staging (N = 540)</b>		
STAGE I	7	1,2
STAGE II	167	31
STAGE III	242	44,9
STAGE IV	124	22,9
<b>Histological type (N = 777)</b>		
InvasivDuctalCarcinoma (IDC)	618	79,6
Invasive LobularCarcinoma (ILC)	70	9
Other type	89	11,4
<b>Immunohistochemistry (N = 425)</b>		
TNBC	172	40,4
luminal A	119	28
luminal B	27	6,4
HER2+	107	25,2
<b>Treatment (N = 777)</b>		
Curative	604	77,7
Palliative	138	17,7
Not treated	35	4,6

The ethnic distribution of BC women showed that 397 (50.1%) patients were white Moors, 263 (33.16%) black Moors and 133 (16.7 %) of black African descent.

## Pathological features

Out of the 793 included women, breast cancer was bilateral in 25 (3%) of cases. In 417 patients (52.6%), the right breast was affected.

The average diameter (measured at the widest point) of the primary tumor was 4 cm with 68.1% of recorded patients having a tumor size smaller than 5 cm against 31.9% showing a diameter above 5 cm.

Cells abnormality was diagnosed with poorly differentiated status (grade III) in 185 (31.8%) patients. Moderately differentiated (grade II) and differentiated (grade I) tumors were found respectively in 334 (57.2%) and 67 (11.4%) women. Breast cancer was at stage I in 7 (0.13 %), stage II in 167 (31%), stage III in 242 (44.9 %) and metastatic stage IV in 124 (22.6%) patients.

Cancer stretching into breast surrounding tissues showed presence of invasive ductal carcinomas (IDC) in 618 (79.6%) and invasive lobular carcinoma (ILC) in 70 (9 %) slides. Less common types were also observed (11.4 %).

In 425 breast cancer patients with satisfactory immunohistochemical data, 172 (40.4%) were classified triple negative breast cancer (TNBC) as no above cut off antibody staining was detected simultaneously for ER, PR and HER-2 receptors. Molecular classification of the remaining 253 (59.6%), non-TNBC patients, gave in order 119 (28 %) luminal A, 27 (6.2 %) luminal B and 107 (25.4%) HER2-positive (Table 1).

Comparison of the relevant demographic, clinical and histochemical characteristics between TNBC and non-TNBC patients showed, despite slight differences in percentages, no statistically significant difference ( $p < 0.05$ ) in median age at diagnosis, family history, ethnicity, menopausal status, proportion of cases with clinical stage or histological grade, treatment and recurrence was observed (Table 2).

Table 2

Comparison of epidemiological and clinico-pathological features between TNBC and NON-TNBC patients

<b>Parameters</b>	<b>NON-TNBC (N = 253)</b>	<b>TNBC (N = 172)</b>	<b><math>\chi^2</math> Value</b>	<b>PValue</b>
<b>Age</b>			4,845	0,088
< 35	39(15,67%)	34(19,56%)		
[35–55]	147(58,2%)	75(43,475%)		
> 55	67(26,11%)	63(36,9%)		
<b>Family history</b>			1,616	0,204
Present	15(6%)	32(18,93%)		
Absent	238(94%)	139 (80,07%)		
<b>Ethnicity</b>			5,343	0
Moors whiteMoors	103 (40,7%)	49(28,5%)		
Black Moors	16 (9,3%)	107(62,7%)		
Black Africans	56 (22,13%)	16 (9,3%)		
<b>Menopause</b>			,704	0,401
Premenopause	149(59%)	113(66%)		
Postmenopause	104(40%)	59(34%)		
<b>Histological type</b>			,099	0,753
Invasivecarcinoma	209(83,58%)	143(83,5%)		
Others	44(16,4%)	29(16,5%)		
<b>Histologicalgrading</b>			4,813	0,185
Grade I	30(11,11%)	6(3,2%)		
Grade II	158(62,8%)	111(64,8%)		
Grade III	65(26,11%)	55(32%)		
<b>Staging</b>			3,652	0,455
STAGE I	2(0,14%)	0(0%)		
STAGE II	70(27,6%)	56(32,9%)		
STAGE III	101(40,2%)	66(38,4%)		
STAGE IV	48(19%)	24(14,2%)		

<i>Parameters</i>	<b>NON-TNBC (N = 253)</b>	<b>TNBC (N = 172)</b>	<b><math>\chi^2</math> Value</b>	<b>PValue</b>
<b>Treatment</b>			2,549	0,28
curative	208(82,2%)	146(84,6%)		
Palliative	45(17,8%)	26(15,4%)		
<b>Local recurrence or distant metastasis</b>	(n = 58)22,9%	(n = 68)39,5%	4,041	0
Local recurrence	2	3		
Distant metastasis	56	65		

## Outcome

Out of 189 women diagnosed with breast cancer in 2017, 120 were still alive and only 26% of those diagnosed in 2018 have died giving a 3- and 2-year observed survival rate of 63% and 74% respectively. BC did not return in most of these patients as 88% and 95% of women diagnosed respectively in 2017 and 2018 did not show any local or distant recurrence.

## Discussion

In this study, we have first addressed the main demographic and clinical characteristics of breast cancer in a cohort of patient women referred to the CNO (Centre National d'Oncology) and assessed the outcome of cancer in the context of these factors. Out of 11175 patient files of all cancer types, BC was the most common in the cohort population (16.56%), particularly in women (30.9%). This standing was also reported by a ten years study (from 2000 to 2009) which included 3305 histological samples analyzed by the department of anatomic pathology (Hopital National de Nouakchott) and showed a prevalence of 14.6% in the whole cohort and 25.2% among the female population[10].As our study was conducted in the following decade of the previous work and covered the single state referring facility for cancer, the data generated were therefore likely representative of the disease evolution in the country. Their concordance reflected an increase in the incidence of breast cancer in our population. Similar percentages of breast cancer in women were reported in neighboring populations such as in Morocco(36%)[8, 11]and Senegal (26.1 %) [12].

Most women diagnosed with breast cancer (69%) in our study were ages 55 or less. Registries and community-based studies showed that 70% of women with breast cancer in Sub-Saharan Africa were in the same age group [13]. The mean age of 49 years we observed was thus close to the 48 years reported globally in Africa [14] and 46 years in British black women [15]. This relatively early onset of breast cancer was lower than late age of 67 years at presentation in white British women [15]. Pre-menopausal status

was also predominant in our cohort (63 %) as in two-thirds of black African women with BC [16–17] while most of European women (80 %) were postmenopausal at presentation with the disease [18].

We also observed that most patients (66%) had moderate to poorly differentiated tumors with widely spread stage 3 (44%) or metastasized (22%) cancer when diagnosed with BC. A similar outline was reported in a 12 sub-Saharan countries study (Zimbabwe, Benin, Seychelles, Ethiopia, Mauritius, South Africa, Kenya, Mozambique, Mali, Namibia, Uganda and Cote d'Ivoire) showing that 64.9% of women patients were diagnosed in late stages, when treatment became weakly effective, of which 18.4% being metastatic at diagnosis [19]. This late advanced stage at presentation, very likely accentuated by poor socioeconomic conditions and lack of access to adequate healthcare, could be therefore determinant in the low 2- and 3-year observed survival rate of 74% and 64% observed in our cohort and the overall relative survival (RS) of 61.4% (59.1–63.5) at year 3 and 52.3% (49.9–54.6) at year 5 [19] in BC patients across sub-Saharan Africa. In contrast, 79% and 89% of women with breast cancer respectively in Europe and the US had not died from their cancer 5 years later after diagnosis [20].

Despite evidences reported from many large cohort studies linking overweight to breast cancer risk [21–22], nearly 40% of women worldwide were overweight in 2020 [23].

We have shown a high cumulative prevalence of overweight and obesity among our patients. Obesity was for centuries desirable and a sign of wealth in various African countries [24]. A traditional practice of force-feeding teenage girls (known as *leblouh* in our country) has indeed been prevalent in Mauritania and several other African populations [25–26].

Although lifestyle choices and low provision of healthcare services in African populations may be determinant in the disease expected development, various studies have shown that other risk factors may take part in BC prognosis such as patient race or ethnic origin, parents' consanguinity and age at onset [27–29].

The comparable early age at breast cancer onset observed in our cohort, globally in Sub-Saharan [13] and British black women [15] against a relatively late age of 67 years in white British women at presentation [18] was in this context relevant. African-American women have also higher rates of grade 3 than their Caucasian counterparts [30–31].

Race related differences among BC patients have been attributed to various hereditary grounds including breast cancer susceptibility genes and endogenous hormones [32]. For instance, in the US, the frequency of samples tested negative for receptors of progesterone, estrogen and HER2 protein (TNBC) was higher in African-American women (28%) compared to Caucasian women (12%) [33]. The Mauritanian population is composed of three main groups all Muslims but of different race origin [34]: the white Maures (WM) speaking Hassaniya, a berber-arab dialect. This group ethnically and culturally self-identifies with the neighboring North Africa populations. The black Maures (BM) also speaking Hassaniya but share the same race origin with the third group, the black African Mauritians (BAM), as both descended from native sub-Saharan Africans.

The global TNBC prevalence (40.4%) observed in this study was intermediate between the percentages of 28.5% in the white Moors and 71.51 % in the black Moors-black Africans group respectively. The frequency observed in the white Moors (28.5%) although slightly higher, was comparable to the percentages in North African populations [35–36]. The frequencies in black Moors-black Africans group, is also similar to those reported in sub-Saharan African women-based studies[37–38] which is consistent with the common African ascendance above mentioned.

This ethnically associated repartition of percentages in TNBC also concords with the distribution of other biomarkers we reported previously in our population [39–40]. However, although differences of percentages between TNBC and NTNBC patients were observed, all parameters we analyzed did not reach the level of statistical significance set.

## **Conclusions**

We have provided data from a representative cohort on the frequencies of BC in Mauritania, evaluated the main demographic and clinical characteristics which may affect the disease prognosis. The results, consistent with already published studies support a genetic basis of breast cancer in our population. Further studies increasing the cohort size and extending the time span of following the patients may optimize data for significant correlation assessment.

## **Declarations**

### ***Ethics approval and consent***

Approval to this study was given by the ethics committee of the Université de Nouakchott Al-Asriya, Mauritania. The informed consent of patients referred to the CNO was obtained. All methods were carried out in accordance with relevant guidelines and regulations.

### ***Availability of data and materials***

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### ***Competing interests***

The authors declare that they have no competing interests.

### ***Funding***

no specific funding was obtained for this study carried out between the UNA and the CNO.

### ***Authors' contributions***

**SBR** collected and organized all cancer files; She contributed to epidemiological and Immunohistochemistry data analysis; **CTH** contributed in pathological data analysis; **EZ** initiated the paper conception and contributed to the manuscript progress; **MS** contributed to epidemiological data analysis; **FV** contributed to epidemiological data analysis; **MVZ** contributed to pathological data analysis; **AT** examined Immunohisto chemical slides (IHC) and contributed in paper conception and writing; **MK** contributed in paper conception and paper writing; **AH** were the major contributor in coordinating all data analysis and writing the manuscript. All authors read and approved the final manuscript.

## References

1. [Hélène Sancho-Garnier, Marc Colonna](#), Breast cancer epidemiology *Presse Med.* 2019 Oct; 48(10):1076-1084.
2. [Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I](#) Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. *Lancet Glob Health.* 2016 Dec;4(12):923-e935.
3. [Foerster M, Anderson BO, McKenzie F, Galukande M, Anele A, Adisa C, Zietsman A, Schuz J, Dos Santos Silva I, McCormack V.](#) Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study. *Breast Cancer Res.* 2019 Aug 13;21(1):93.
4. [Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, Alo RA, Payton M, Tchounwou, PB.](#) Health and Racial Disparity in Breast Cancer. *Adv Exp Med Biol.* 2019;1152:31-49.
5. [Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, et al.](#) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *J Clin Oncol.* 2015;33(4):304–11.
6. [Rousset-Jablonski C, Gompel A.](#) Maturitas Screening for familial cancer risk: Focus on breast cancer. 2017; 105:69-77.
7. [Zheng Y, Walsh T, Gulsuner S, Casadei S, Lee MK, Ogundiran TO, Ademola A, Falusi AG, Adebamowo CA, Oluwasola AO, Adeoye A, Odetunde A, Babalola CP, Ojengbede OA, Odedina S, Anetor I, Wang S, Huo D, Yoshimatsu TF, Zhang J, Felix GES, King MC, Olopade OI.](#) Inherited Breast Cancer in Nigerian Women. *J Clin Oncol.* 2018 Oct 1;36(28):2820-2825.
8. [Imen Bannour, Raja Briki, Faten Zrairi and Thouraya Zahmoul.](#) Breast cancer in the Maghreb : epidemiology and control strategies. *La Tunisie médicale.* 96(10-11):658-664.
9. [Samuel Nambile Cumber, Keneth Nkeh Nchanji & Joyce Mahlako Tsoka-Gwegweni](#) Breast cancer among women in sub-Saharan Africa: prevalence and a situational analysis. *Southern African Journal of Gynaecological Oncology* .2017; 9,2.35-37.
10. [Nacer Dine Ould Mohamed Baba and Catherine Sauvaget.](#) Cancer in Mauritania: results of 10 years from the hospital register in Nouakchott *Pan Afr Med J.* 2013; 14.149.256
11. [Fatima Zahra Mouh,<sup>1,2</sup> Meriem Slaoui,<sup>1,2</sup> Rachid Razine,<sup>3</sup> Mohammed EL Mzibri,<sup>2</sup> and Mariam Amrani](#) Clinicopathological, Treatment and Event-Free Survival Characteristics in a Moroccan Population of

- Triple-Negative Breast Cancer [Breast Cancer \(Auckl\)](#). 2020; 14: 1178223420906428.
12. Megan Burke Fitzpatrick et al. Pathology of Senegalese breast cancers. *Pan African Medical Journal*. 2019;34:67.
  13. Black, E., Richmond, R. Improving early detection of breast cancer in sub-Saharan Africa: why mammography may not be the way forward. *Global Health*2019;15, 3.
  14. Da Costa Vieira RA, Biller G, Uemura G, Ruiz CA, Curado MP. Breast cancer screening in developing countries. *Clinics (Sao Paulo)* 2017; 72:244–53.
  15. [Roger Dobson](#). Black women have a higher risk of breast cancer than white women. *BMJ*. 2008 Jan 19; 336(7636): 116.
  16. [Dominique Sighoko](#) <sup>1</sup> , [BakarouKamaté](#), [Cheick Traore](#), [BrahimaMallé](#), [Bourama Coulibaly](#), [Agnès Karidiatou](#), [Coulibaly Diallo](#), [Ebrima Bah](#), [Valerie McCormack](#), [Richard Muwonge](#), [Denis Bourgeois](#), [Emmanuelle Gormally](#), [Maria Paula Curado](#), [Siné Bayo](#), [Pierre Hainaut](#). Breast cancer in pre-menopausal women in West Africa: analysis of temporal trends and evaluation of risk factors associated with reproductive life *Breast* 2013;22(5):828-35.
  17. Pace LE, Shulman LN. Breast cancer in sub-saharan Africa: challenges and opportunities to reduce mortality. *Oncologist*.2016; 21:739–44.
  18. Emily Heer, [Andrew Harper](#), [Noah Escandor](#), Hyuna Sun, Valerie McCormack, Miranda M Fidler-Benaoudia Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. 2020,8:1027-1037.
  19. [Walburga Y. Joko-Fru](#), [Adalberto Miranda-Filho](#), [Isabelle Soerjomataram](#), [Marcel Egue](#), [Marie-Therese Akele-Akpo](#), [Guy N'da](#), [Mathewos Assefa](#), [Nathan Buziba](#) et al., Breast cancer survival in sub Saharan Africa by age, stage at diagnosis and human development index: A population based registry study. *International Journal of Cancer*. 2019: 146, 5.
  20. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, Coebergh JW, et , carcinoma survival in Europe and the United States *Cancer*.2004 (4):715-22.
  21. Neuhaus ML, Aragaki AK, Prentice RL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: A secondary analysis of the Women's Health Initiative randomized clinical trials. *JAMA Oncology*. 2015; 1(5):611-621.
  22. [Kyuwan Lee](#), [Laura Kruper](#), [Christina M. Dieli-Conwright](#), and [Joanne E. Mortimer](#). The Impact of Obesity on Breast Cancer Diagnosis and Treatment. *Curr Oncol Rep*. 2019; 21(5): 41.
  23. Obesity and overweight. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>. Accessed 30 Sept 2020
  24. [Bridget Adeboye](#), [Giovanna Bermano](#), [Catherine Rolland](#), Obesity and its health impact in Africa: a systematic review. *Cardiovasc J Afr*. 2012; 23(9): 512–521.
  25. Hitchen, Mike. "Mauritania: Force-feeding of young girls waning, replaced by drugs formulated for livestock". Retrieved2019-12-08.

26. Rguibi, M.; Belahsen, R. Fattening practices among Moroccan Saharawi women. *Eastern Mediterranean Health*. 2006.12 (5), 619-624.
27. Momenimovahed Z, Salehiniya H. Epidemiological characteristics and risk factors for breast cancer in the world. *Breast Cancer (Dove Med Press)*. 2019; 11:151–64.
28. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 2017; 317(23):2402–2416.
29. Foluso O. Ademuyiwa and Olufunmilayo I. Olopade Racial differences in genetic factors associated with breast cancer. *Cancer and Metastasis* .2003;22, 47–53.
30. Evelyn Jiagge, Aisha Souleiman Jibril; Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer, *Ann Surg Oncol*. 2016;23(12):3843-3849.
31. Danforth, D.N., Jr. Disparities in breast cancer outcomes between Caucasian and African American women: A model for describing the relationship of biological and non biological factors. *Breast Cancer Res*. 2013, 15, 208.
32. Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE. [Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II](#). *Breast Cancer Res*. 2013;15(2):19.
33. [Sumit Siddharth](#) and [Dipali Sharma](#) Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. *Cancers (Basel)*. 2018; 10(12): 514.
34. The world Bank In Mauritania. 2019. <https://www.worldbank.org/en/country/mauritania/overview>
35. Fourati A, Boussen H, El May MV, et al. Descriptive analysis of molecular subtypes in Tunisian breast cancer. *Asia Pac J Clin Oncol*. 2014;10(2):69-74.
36. El-Hawary AK, Abbas AS, Elsayed AA, Zalata KR. Molecular subtypes of breast carcinoma in Egyptian women: clinicopathological features. *Pathol Res Pract*. 2012 ;208(7):382-386.
37. Huo, D.; Ikpatt, F.; Khramtsov, A.; Dangou, J.M.; Nanda, R.; Dignam, J.; Zhang, B.; Grushko, T.; Zhang, C; Oluwasola, O.; et al. Population differences in breast cancer: Survey in indigenous African women reveal over-representation of triple-negative breast cancer. *J. Clin. Oncol*. 2009, 27, 4515–4521.
38. Ly, M.; Antoine, M.; Dembele, A.K.; Levy, P.; Rodenas, A.; Toure, B.A.; Badiaga, Y.; Dembele, B.K.; Bagayogo, D.C.; Diallo, Y.L.; et al. High incidence of triple-negative tumors in sub-saharan Africa: A prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. *Oncology* 2012, 83, 257–263.
39. Hadrami M, Bonnet C, Zeitz C, Veten F, Biya M, Hamed CT, Condroyer C, Wang P, Sidi MM, Cheikh S, Zhang Q, Audo I, Petit C, Houmeida. A. [Mutation profile of glaucoma candidate genes in Mauritanian families with primary congenital glaucoma](#). *Mol Vis*. 2019 ;13; 25:373-381.
40. Hamed CT, Meiloud G, Veten F, Hadrami M, Ghaber SM, Boussaty EC, Habti N, Houmeida A. [HLA class I \(-A, -B, -C\) and class II \(-DR, -DQ\) polymorphism in the Mauritanian population](#). *BMC Med Genet*. 2018;19(1):2.

# Figures



Figure 1

Proportions (%) of common cancers referred to the CNO during the period of 2009 to 2020: A (whole cohort); B (females); C(males).




Figure 2

Breast cancer incidence between 2009 and 2020